323 related articles for article (PubMed ID: 19527453)
21. Characterization of cross-protection by genetically modified live-attenuated Leishmania donovani parasites against Leishmania mexicana.
Dey R; Natarajan G; Bhattacharya P; Cummings H; Dagur PK; Terrazas C; Selvapandiyan A; McCoy JP; Duncan R; Satoskar AR; Nakhasi HL
J Immunol; 2014 Oct; 193(7):3513-27. PubMed ID: 25156362
[TBL] [Abstract][Full Text] [Related]
22. Effective immunization against cutaneous leishmaniasis with defined membrane antigens reconstituted into liposomes.
Russell DG; Alexander J
J Immunol; 1988 Feb; 140(4):1274-9. PubMed ID: 3257774
[TBL] [Abstract][Full Text] [Related]
23. Co-administration of rectal BCG and autoclaved Leishmania major induce protection in susceptible BALB/c mice.
Soudi S; Hosseini AZ; Hashemi SM
Parasite Immunol; 2011 Oct; 33(10):561-71. PubMed ID: 21781137
[TBL] [Abstract][Full Text] [Related]
24. Comparison of potential protection induced by three vaccination strategies (DNA/DNA, Protein/Protein and DNA/Protein) against Leishmania major infection using Signal Peptidase type I in BALB/c mice.
Rafati S; Ghaemimanesh F; Zahedifard F
Vaccine; 2006 Apr; 24(16):3290-7. PubMed ID: 16481076
[TBL] [Abstract][Full Text] [Related]
25. Effective immunization against cutaneous leishmaniasis with recombinant bacille Calmette-Guérin expressing the Leishmania surface proteinase gp63.
Connell ND; Medina-Acosta E; McMaster WR; Bloom BR; Russell DG
Proc Natl Acad Sci U S A; 1993 Dec; 90(24):11473-7. PubMed ID: 8265576
[TBL] [Abstract][Full Text] [Related]
26. DNA based vaccination with a cocktail of plasmids encoding immunodominant Leishmania (Leishmania) major antigens confers full protection in BALB/c mice.
Ahmed SB; Touihri L; Chtourou Y; Dellagi K; Bahloul C
Vaccine; 2009 Jan; 27(1):99-106. PubMed ID: 18951941
[TBL] [Abstract][Full Text] [Related]
27. Human T cell responses to gp63, a surface antigen of Leishmania.
Russo DM; Burns JM; Carvalho EM; Armitage RJ; Grabstein KH; Button LL; McMaster WR; Reed SG
J Immunol; 1991 Nov; 147(10):3575-80. PubMed ID: 1940356
[TBL] [Abstract][Full Text] [Related]
28. Genetic background influences immune responses and disease outcome of cutaneous L. mexicana infection in mice.
Rosas LE; Keiser T; Barbi J; Satoskar AA; Septer A; Kaczmarek J; Lezama-Davila CM; Satoskar AR
Int Immunol; 2005 Oct; 17(10):1347-57. PubMed ID: 16141242
[TBL] [Abstract][Full Text] [Related]
29. [Immune protective mechanisms of gene vaccines with co-expressing bcr-abl fusion gene fragment and mouse IL-7 gene].
Ji MC; Jiang YW; Liu W; Guan J; Qian L; Gong WJ
Zhonghua Zhong Liu Za Zhi; 2007 Feb; 29(2):93-5. PubMed ID: 17645839
[TBL] [Abstract][Full Text] [Related]
30. Partial protective responses induced by a recombinant cysteine proteinase from Leishmania (Leishmania) amazonensis in a murine model of cutaneous leishmaniasis.
Fedeli CE; Ferreira JH; Mussalem JS; Longo-Maugéri IM; Gentil LG; dos Santos MR; Katz S; Barbiéri CL
Exp Parasitol; 2010 Feb; 124(2):153-8. PubMed ID: 19735658
[TBL] [Abstract][Full Text] [Related]
31. Protective immunogenicity of the paraflagellar rod protein 2 of Leishmania mexicana.
Saravia NG; Hazbón MH; Osorio Y; Valderrama L; Walker J; Santrich C; Cortázar T; Lebowitz JH; Travi BL
Vaccine; 2005 Jan; 23(8):984-95. PubMed ID: 15620471
[TBL] [Abstract][Full Text] [Related]
32. Development of dominant epitope-based vaccines encoding Gp63, Kmp-11 and Amastin against visceral leishmaniasis.
Zhang J; He J; Liao X; Xiao Y; Liang C; Zhou Q; Chen H; Zheng Z; Qin H; Chen D; Chen Q; Li J; Chen J
Immunobiology; 2021 May; 226(3):152085. PubMed ID: 33910113
[TBL] [Abstract][Full Text] [Related]
33. Leishmania amazonensis: humoral response to amastigote excreted-antigens in murine leishmaniasis.
Hernández-Chinea C
Exp Parasitol; 2007 Aug; 116(4):492-6. PubMed ID: 17349625
[TBL] [Abstract][Full Text] [Related]
34. Leishmania major: immune response in BALB/c mice immunized with stress-inducible protein 1 encapsulated in liposomes.
Badiee A; Jaafari MR; Khamesipour A
Exp Parasitol; 2007 Feb; 115(2):127-34. PubMed ID: 16979165
[TBL] [Abstract][Full Text] [Related]
35. Differential dependence on target site tissue for gene gun and intramuscular DNA immunizations.
Torres CA; Iwasaki A; Barber BH; Robinson HL
J Immunol; 1997 May; 158(10):4529-32. PubMed ID: 9144463
[TBL] [Abstract][Full Text] [Related]
36. Effect of Prophylactic Vaccination with the Membrane-Bound Acid Phosphatase Gene of
Burgos-Reyes MA; Baylón-Pacheco L; Espíritu-Gordillo P; Galindo-Gómez S; Tsutsumi V; Rosales-Encina JL
J Immunol Res; 2021; 2021():6624246. PubMed ID: 33928168
[TBL] [Abstract][Full Text] [Related]
37. Immunization strategies against visceral leishmaniosis with the nucleosomal histones of Leishmania infantum encoded in DNA vaccine or pulsed in dendritic cells.
Carrión J; Folgueira C; Alonso C
Vaccine; 2008 May; 26(20):2537-44. PubMed ID: 18400342
[TBL] [Abstract][Full Text] [Related]
38. Cysteine proteinase type III is protective against Leishmania infantum infection in BALB/c mice and highly antigenic in visceral leishmaniasis individuals.
Khoshgoo N; Zahedifard F; Azizi H; Taslimi Y; Alonso MJ; Rafati S
Vaccine; 2008 Oct; 26(46):5822-9. PubMed ID: 18804512
[TBL] [Abstract][Full Text] [Related]
39. Immunization with the DNA-encoding N-terminal domain of proteophosphoglycan of Leishmania donovani generates Th1-type immunoprotective response against experimental visceral leishmaniasis.
Samant M; Gupta R; Kumari S; Misra P; Khare P; Kushawaha PK; Sahasrabuddhe AA; Dube A
J Immunol; 2009 Jul; 183(1):470-9. PubMed ID: 19542458
[TBL] [Abstract][Full Text] [Related]
40. Priming with a very low dose of DNA complexed with cationic block copolymers followed by protein boost elicits broad and long-lasting antigen-specific humoral and cellular responses in mice.
Voltan R; Castaldello A; Brocca-Cofano E; De Michele R; Triulzi C; Altavilla G; Tondelli L; Laus M; Sparnacci K; Reali E; Gavioli R; Ensoli B; Caputo A
Vaccine; 2009 Jul; 27(33):4498-507. PubMed ID: 19450649
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
